glp-1 side effects cancer and Risk: What Current Research Really Shows GLP-1RA and thyroid cancer: New
Description
The medication has a long half-life of approximately one week, allowing for convenient once-weekly dosing of the injectable formulations
Setmelanotide Setmelanotide is a melanocortin-4 receptor (MC4R) agonist approved to treat genetic obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiencies, as well as BardetBiedl syndrome (BBS), in patients aged 2 years and older [45,46,47]
Deacon CF
However, based on the pharmacological similarity to other incretin-based therapies, similar weight regain is expected once treatment ends
